Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.4000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CERo Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Get insights into the top gainers and losers of Monday's pre-market session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark indices were mixed in premarket. 
Via Benzinga
Topics Stocks
Exposures US Equities
Discover the top movers in Friday's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Friday's pre-market session
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Thursday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish
The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025. 
Via Stocktwits
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.